secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2025-04-22T23:59:59+00:00
Accession:  0001213900-25-034254
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital amends merger pact with Semnur; extends deadline to Sept 2025, addresses Nasdaq delisting
--------------------------------------------------------------------------------

- Amendment allows Denali to extend business combination deadline to Dec 11, 2025, or later if mutually agreed.
- Outside Date for closing merger extended to Sept 30, 2025; if extension effective, Outside Date becomes Extension Date.
- Modifies covenants to address Denali's Nasdaq delisting and subsequent OTC Markets quotation of its securities.
- Denali will use reasonable best efforts to list its units, shares, and warrants on OTC Markets after Nasdaq delisting.
- Other changes include updating blank-check company status and proxy statement requirements for shareholder vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390025034254/0001213900-25-034254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390025034254/ea0239156-8k_denali.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-034254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer